Last week, Sandoz announced new data reportedly showing that its proposed adalimumab biosimilar matches the safety and efficacy profile of Humira^®.  The data was obtained from a long term study of patients with moderate-to-severe chronic plaque psoriasis.  As we reported here, Sandoz has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its proposed adalimumab biosimilar and, as we reported here, Sandoz plans to file an aBLA with the FDA in the second half of 2017.